Development and analytical validation of AB40, AB42, A‐Syn, CD33, P‐Tau 181, Tau, and TREM2 in human serum, plasma, or CSF
Jacqueline Surls, Robyn Vega Ibanez, Lindsey Brown, Josh Kemp · 2025
Read Development and analytical validation of AB40, AB42, A‐Syn, CD33, P‐Tau 181, Tau, and TREM2 in human serum, plasma, or CSF by Jacqueline Surls, Robyn Vega Ibanez, Lindsey Brown, Josh Kemp (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11715825.txt.
Description
Jacqueline Surls and three co-authors report the building and testing of seven lab assays that measure proteins tied to Alzheimer's disease in blood and spinal fluid, in this 2025 paper. Blood tests are simpler and cheaper than spinal fluid tests, but each new assay must prove it measures its target well. The team used a highly sensitive testing platform.
The assays cover amyloid proteins, tau proteins, and markers tied to inflammation and cell stress. Each one passed standard checks for sensitivity, accuracy, stability, and freedom from common interferences. The team reports the working range for each assay in blood and in spinal fluid, plus quality control results across runs. Validated assays of this kind are the groundwork for blood based screening in clinics and drug trials.
Catalog record
| CREATOR | Jacqueline Surls, Robyn Vega Ibanez, Lindsey Brown, Josh Kemp |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |